Journal of Chemistry

Journal of Chemistry / 2017 / Article

Research Article | Open Access

Volume 2017 |Article ID 9161505 |

Emel Pelit, "Synthesis of Isoxazolopyridines and Spirooxindoles under Ultrasonic Irradiation and Evaluation of Their Antioxidant Activity", Journal of Chemistry, vol. 2017, Article ID 9161505, 9 pages, 2017.

Synthesis of Isoxazolopyridines and Spirooxindoles under Ultrasonic Irradiation and Evaluation of Their Antioxidant Activity

Academic Editor: Mohamed Afzal Pasha
Received20 Jun 2017
Accepted08 Aug 2017
Published12 Oct 2017


New polycyclic-fused isoxazolo[,5-e]pyridines and spirooxindoles were obtained via multicomponent reaction of 5-amino-3-methylisoxazole, indan-1,3-dione, and aromatic aldehydes and reaction of 5-amino-3-methylisoxazole, isatin, and -diketones in the presence of (±)-camphor-10-sulfonic acid as an effective and nontoxic organocatalyst under ultrasound-promoted conditions. The antioxidant activity of the novel synthesized compounds was studied.

1. Introduction

Multicomponent reactions allow the building of several new bonds in a single step and therefore these one-pot reactions are one of the most attractive topics in synthetic chemistry [1]. These reactions have enormous effectiveness, particularly for the construction of heterocyclic compounds which exhibit a wide range of biological activities [25]. Multicomponent reactions proceed in accordance with green chemistry principles in terms of a high degree of atom economy, easier progress of reactions, decreased reaction times, lack of waste products, and low power consumption [6, 7].

Isoxazole and spirooxindole compounds have exhibited many biological properties such as antibacterial [8], anti-inflammatory [9], anticonvulsant [10], muscle relaxant [11], anti-HIV and anticancer activity [1216], and significant activity in hypertension and Alzheimer’s disease [17, 18]. Consequently, several protocols for the synthesis of isoxazoles and spirooxindoles have been reported [1928].

(±)-Camphor-10-sulfonic acid (CSA) is an effective, safe, water-soluble, and reusable organocatalyst for various organic reactions, for instance, Friedel-Crafts reactions [29], synthesis of dioxabicyclo[3.3.1]nonane and -amino naphthol compounds [30, 31], and synthesis of spirocyclic compounds [32], and is also frequently used in the optical resolution of amines [33].

It is important to develop new synthetic processes that provide better environmental performance in synthetic organic chemistry [34]. Numerous organic reactions can be effectively achieved in higher yields, shorter reaction times, and milder reaction conditions under ultrasonic irradiation due to cavitational collapse [3540].

This work aims to study the synthesis of isoxazolopyridines and spirooxindoles under ultrasonic irradiation in the presence of (±)-CSA as an organocatalyst. Antioxidants are being increasingly noticed for the prevention of the damaging influence of free radicals in the human body [41]. Hence, to expand biological curiosity to isoxazolopyridine and spirooxindole compounds, the new synthesized compounds were tested for their free radical scavenging activity (determined for DPPH), reducing activity (reduction of the Fe3+/ferricyanide complex to its ferrous form), metal chelating (chelating activity capacity of ferrous ions) activity, superoxide scavenging activity, and total antioxidant activity.

2. Experimental

2.1. Materials and Methods

NMR spectra were determined on a Bruker Avance III-500 MHz NMR. Chemical shifts are given in ppm downfield from Me4Si in DMSO- solution. Coupling constants are given in Hz. The FTIR spectra were recorded on a Perkin-Elmer FT-IR spectrometer (ATR) and absorption frequencies are reported in cm−1. MS spectra were recorded on an AB Sciex 3200 QTRAP LC-MS/MS. Elemental analyses were measured with CHNS-932 LECO apparatus and were in good agreement (±0.2%) with the calculated values. Ultrasonication was performed in an Alex Ultrasonic Bath with a frequency of 32 kHz and a power of 230 W. The internal dimensions of the ultrasonic cleaner tank were  mm with liquid holding capacity of 3 L. The reactor was a 100 mL Pyrex round-bottom flask. The reaction flasks were suspended in the center of the bath, and the addition or removal of water controlled the temperature of the water bath. Melting points were measured on a Gallenkamp melting-point apparatus. TLC was conducted on standard conversion aluminum sheets precoated with a 0.2 mm layer of silica gel. All reagents were commercially available.

2.2. General Procedure for the Synthesis of Isoxazolopyridine Derivatives (4a–e and 5f–h) under Ultrasonic Irradiation

A mixture of CSA (34.8 mg, 0.15 mmol), 5-amino-3-methylisoxazole, (1.00 mmol), indan-1,3-dione (1.00 mmol), and aromatic aldehydes (1.00 mmol) in 5 mL EtOH was irradiated with ultrasound of low power at 70°C for the period of time indicated in Scheme 1 and Table 2. After completion of the reaction, as indicated by TLC monitoring, the resultant solid was washed with water and crystallized from ethanol to give products 4a–e and 5f–h.

2.3. General Procedure for the Synthesis of Spirooxindole Derivatives (8a–d) under Ultrasonic Irradiation

A mixture of CSA (23.2 mg, 0.10 mmol), 5-amino-3-methylisoxazole, (1.00 mmol), isatin (1.00 mmol), and -diketones (1.00 mmol) in 5 mL EtOH was irradiated with ultrasound of low power at 70°C for the period of time indicated in Scheme 2 and Table 3. After completion of the reaction, as indicated by TLC monitoring, the resultant solid was washed with water and crystallized from ethanol to give products 8a–d.

2.4. Free Radical Scavenging Activity

The free radical scavenging activity was determined by 1,1-diphenyl-2-picryl-hydrazyl (DPPH). The activity was assayed according to the methodology described by Brand-Williams et al. [42]. 20 mg/L DPPH in methanol was prepared and 1.5 mL of this solution was added to 0.75 mL of isoxazolopyridine or spirooxindole compounds solution in water at various concentrations (25–400 μg/mL). After 30 minutes the absorbance was measured at 517 nm. The inhibition activity percentage was calculated according to the following equation: ( is the control absorbance and is the sample solution absorbance).

2.5. The Reducing Power Assay

The reducing power of newly synthesized compounds was assayed according to the methodology of Oyaizu [43]. Various concentrations of compounds (25–400 μg/mL) in 1 mL of distilled water were mixed with 0.2 M phosphate buffer and 2.5 mL of potassium ferricyanide [K3Fe(CN)6]. This mixture was incubated at 50°C for 30 minutes and trichloroacetic acid (2.5 mL, 10%, w/v) was added to the mixture and then centrifuged at 3000 rpm for 10 min. Lastly, 2.5 mL of solution was mixed with 0.5 mL FeCl3 and distilled water (2.5 mL) and then the absorbance was measured at 700 nm.

2.6. Metal Chelating Activity

The ferrous ions’ (Fe2+) chelating activities of the isoxazolopyridines, spirooxindoles, and standards were investigated according to the methodology described by Decker and Welch [44]. 1 mL of various concentrations (25–400 μg/mL) of the newly synthesized compounds was mixed with 3.7 mL of water. This mixture was incubated for 30 minutes with 2 mM FeCl2. Afterward, 5 mM ferrozine was added and left standing at room temperature for 10 min. The absorbance of the resulting solution was measured at 562 nm.

2.7. Superoxide Scavenging Activity

The superoxide anion scavenging activity of isoxazolopyridine and spirooxindole compounds was done according to the methodology described by Liu et al. [45]. The superoxide radicals were formed in 3 mL of 16 mM Tris-HCl buffer which contained 1 mL of 50 μM NBT solution, 1 mL of 78 μM NADH solution, and a sample solution of the newly synthesized compounds (25–400 μg/mL) in water. 1 mL of 10 μM phenazine methosulphate (PMS) solution was added to the mixture. Then the mixture was incubated at 25°C for 5 min and the absorbance at 560 nm was measured.

2.8. Total Antioxidant Activity Assay

The total antioxidant activity of isoxazolopyridine and spirooxindole compounds was assayed according to the thiocyanate method described by Mitsuda et al. [46]. The solution of isoxazolopyridine and spirooxindole compounds (150 μg/mL) in 2.5 mL of 0.04 M potassium phosphate buffer was added to 2.5 mL of linoleic acid emulsion in 0.04 M potassium phosphate buffer. This mixed solution (5 mL) was incubated at 37°C. For the period of incubation, 0.1 mL of the mixture was diluted with 3.7 mL of methanol at regular terms, and then 0.1 mL of 30% ammonium thiocyanate and 0.1 mL of 20 mM ferrous chloride in 3.5% hydrochloric acid were added. The absorbance was measured at 500 nm. This step was repeated every 10 h until the control reached its maximum absorbance value.

3-Methyl-4-phenyl-4H-indeno[1,2-b]isoxazolo[4,5-e]pyridin-5(10H)-one (4a). Red powder (EtOH), Yield (71%), m.p. 242–244°C; IR (ATR), /: 3432 (NH), 3164, 3068 (arom. CH), 2857 (aliph. CH), 1699 (C=O); 1H NMR (DMSO-) /ppm: 1.86 (s, 3H, Me), 5.11 (s, 1H, CH), 7.21 (d, 1H,  Hz, Ar-H), 7.29–7.46 (m, 4H, Ar-H), 7.50–7.75 (m, 4H, Ar-H), 12.10 (s, 1H, NH); 13C NMR (DMSO-): /ppm 190.36 (C=O), 160.32 (Ar-C), 159.08 (Ar-C), 155.19 (Ar-C), 144.27 (Ar-C), 140.72 (Ar-C), 136.05 (Ar-CH), 133.39 (Ar-CH), 130.34 (Ar-CH), 129.58 (Ar-CH), 128.28 (Ar-CH), 127.84 (Ar-CH), 126.59 (Ar-CH), 123.59 (Ar-CH), 120.49 (Ar-CH), 119.22 (Ar-C), 108.28 (Ar-C), 97.40 (Ar-C), 34.48 (CH), 9.90 (Me); MS: (ESI) 316.4 [M++2], 314.1 [M+]+, 298.4 [M+−16], 106.0 [M+−208]. Anal. Calcd for C20H14N2O2: C, 76.42; H, 4.49; N, 8.91. Found: C, 76.50; H, 4.53; N, 8.86.

4-(3-Methyl-5-oxo-5,10-dihydro-4H-indeno[1,2-b]isoxazolo[4,5-e]pyridin-4-yl)benzonitrile (4b). Red powder (EtOH), Yield (76%), m.p. 257–259°C; IR (ATR) /cm−1: 3432 (NH), 3151, 3106 (arom. CH), 2997, 2920 (aliph. CH), 2231 (C≡N), 1713 (C=O); 1H NMR (DMSO-): /ppm 1.82 (s, 3H, Me), 5.09 (s, 1H, CH), 7.25 (d, 1H,  Hz, Ar-H), 7.36–7.56 (m, 4H, Ar-CH), 7.77–7.82 (m, 3H, Ar-H), 12.18 (s, 1H, NH); 13C NMR (DMSO-): /ppm 190.20 (C=O), 160.64 (Ar-C), 158.96 (Ar-C), 155.71 (C≡N), 149.47 (Ar-C), 135.84 (Ar-C), 133.27 (Ar-C), 132.36 (Ar-CH), 132.01 (Ar-CH), 131.81 (Ar-CH), 130.52 (Ar-CH), 130.09 (Ar-CH), 129.02 (Ar-CH), 120.60 (Ar-CH), 119.43 (Ar-CH), 118.76 (Ar-C), 109.52 (Ar-C), 107.18 (Ar-C), 96.51 (Ar-C), 34.62 (CH), 9.88 (Me); MS: (ESI) 338.0 [M+−1], 321.8 [M+−18], 296.6 [M+−43], 221.3 [M+−118], 138.2 [M+−201], 126.3 [M+−213]. Anal. Calcd for C21H13N3O2: C, 74.33; H, 3.86; N, 12.38. Found: C, 74.40; H, 5.82; N, 12.43.

4-(4-(Benzyloxy)phenyl)-3-metyl-4H-indeno[1,2-b]isoxazolo[4,5-e]pyridin-5(10H)-one (4c). Red powder (EtOH), Yield (78%), m.p. 285–287°C; IR (ATR) /cm−1: 3322 (NH), 3106, 3040 (arom. CH), 2985 (aliph. CH), 1704 (C=O); 1H NMR (DMSO-): /ppm 2.07 (s, 3H, Me), 4.96 (s, 1H, CH), 5.22 (s, 2H, CH2), 7.17–7.44 (m, 5H, Ar-H), 7.52–7.67 (m, 4H, Ar-H), 7.75–7.97 (m, 4H, Ar-H), 12.00 (s, 1H, NH); 13C NMR (DMSO-): /ppm 189.75 (C=O), 167.28 (Ar-C), 159.60 (Ar-C), 157.21 (Ar-C), 147.12 (Ar-C), 145.64 (Ar-CH), 140.67 (Ar-C), 136.95 (Ar-C), 136.27 (Ar-C), 135.89 (Ar-C), 132.68 (Ar-CH), 131.08 (Ar-CH), 130.17 (Ar-CH), 128.46 (Ar-CH), 127.92 (Ar-CH), 127.65 (Ar-CH), 123.57 (Ar-CH), 122.65 (Ar-CH), 121.59 (Ar-CH), 115.24 (Ar-CH), 114.34 (Ar-CH), 113.99 (Ar-CH), 111.89 (Ar-C), 97.54 (Ar-C), 69.45 (CH2), 33.61 (CH), 12.64 (Me); MS: (ESI) 421.5 [M++1], 404.2 [M+−16], 314.0 [M+−106]. Anal. Calcd for C27H20N2O3: C, 77.13; H, 4.79; N, 6.66. Found: C, 77.21; H, 4.73; N, 6.69.

4-(2,4-Difluorophenyl)-3-methyl-4H-indeno[1,2-b]isoxazolo[4,5-e]pyridin-5(10H)-one (4d). Red powder (EtOH), Yield (73%), m.p. 292–294°C; IR (ATR) /cm−1: 3377 (NH), 3101, 3052 (arom. CH), 2924 (aliph. CH), 1727 (C=O); 1H NMR (DMSO-): /ppm 1.84 (s, 3H, Me), 5.19 (s, 1H, CH), 6.98–7.02 (m, 2H, Ar-H), 7.15–7.27 (m, 2H, Ar-H), 7.33–7.57 (m, 3H, Ar-H), 12.15 (s, 1H, NH); 13C NMR (DMSO-): /ppm 190.08 (C=O), 160.62 (Ar-C), 158.75 (Ar-C), 155.81 (Ar-C), 135.94 (Ar-C), 133.33 (Ar-C), 131.99 (Ar-CH), 131.55 (Ar-CH), 130.48 (Ar-CH), 127.01 (Ar-CH), 123.81 (Ar-CH), 120.58 (Ar-CH), 119.34 (Ar-CH), 111.83 (Ar-C), 111.66 (Ar-C), 106.69 (Ar-C), 103.61 (Ar-C), 96.27 (Ar-C), 27.45 (CH), 9.53 (Me); MS: (ESI) 351.4 [M++1], 335.0 [M+−15], 221.1 [M+−129]. Anal. Calcd for C20H12F2N2O2: C, 68.57; H, 3.45; N, 8.00. Found: C, 68.64; H, 3.48; N, 8.07.

3-Methyl-4-(thiophen-2-yl)-4H-indeno[1,2-b]isoxazolo[4,5-e]pyridin-5(10H)-one (4e). Red powder (EtOH), Yield (78%), m.p. 281–283°C; IR (ATR) /cm−1: 3336 (NH), 3120, 3047 (arom. CH), 2928 (aliph. CH), 1706 (C=O); 1H NMR (DMSO-): /ppm 1.86 (s, 3H, Me), 5.11 (s, 1H, CH), 7.20–7.27 (m, 2H, Ar-H), 7.35–7.56 (m, 3H, Ar-H), 7.65–7.83 (m, 2H, Ar-H), 12.13 (s, 1H, NH); 13C NMR (DMSO-): /ppm 190.40 (C=O), 161.94 (Ar-C), 159.11 (Ar-C), 149.09 (Ar-C), 136.66 (Ar-C), 136.14 (Ar-C), 131.97 (Ar-CH), 130.40 (Ar-CH), 125.65 (Ar-CH), 123.80 (Ar-CH), 122.45 (Ar-CH), 121.98 (Ar-CH), 120.55 (Ar-CH), 119.20 (Ar-C), 107.42 (Ar-C), 96.92 (Ar-C), 37.00 (CH), 10.02 (Me); MS: (ESI) 321.2 [M++1], 305.0 [M+−15], 222.0 [M+−98]. Anal. Calcd for C18H12N2O2S: C, 67.48; H, 3.78; N, 8.74. Found: C, 67.53; H, 3.83; N, 8.79.

3-Methyl-4-(3-phenoxyphenyl)-5H-indeno[1,2-b]isoxazolo[4,5-e]pyridin-5-one (5f). Red powder (EtOH), Yield (72%), m.p. 279–281°C; IR (ATR) /cm−1: 3105, 3025 (arom. CH), 2986 (aliph. CH), 1709 (C=O); 1H NMR (DMSO-): /ppm 2.04 (s, 3H, Me), 7.06–7.18 (m, 3H, Ar-H), 7.20–7.61 (m, 8H, Ar-H), 7.76–7.94 (m, 2H, Ar-H); 13C NMR (DMSO-): /ppm 188.27 (C=O), 167.12 (Ar-C), 157.11 (Ar-C), 156.59 (Ar-C), 155.90 (Ar-C), 145.66 (Ar-C), 140.70 (Ar-C), 136.24 (Ar-C), 135.75 (Ar-C), 132.78 (Ar-CH), 130.08 (Ar-CH), 129.76 (Ar-CH), 124.17 (Ar-CH), 123.69 (Ar-CH), 123.55 (Ar-CH), 122.01 (Ar-CH), 121.67 (Ar-CH), 120.02 (Ar-CH), 119.53 (Ar-CH), 118.50 (Ar-CH), 111.76 (Ar-C), 12.32 (Me); MS: (ESI) 405.2 [M++1], 376.2 [M+−28], 361.0 [M+−43], 312.2 [M+−92], 284.2 [M+−120]. Anal. Calcd for C26H16N2O3: C, 77.22; H, 3.99; N, 6.93. Found: C, 77.30; H, 3.92; N, 6.97.

4-(Furan-2-yl)-3-methyl-5H-indeno[1,2-b]isoxazolo[4,5-e]pyridin-5-one (5g). Red powder (EtOH), Yield (80%), m.p. 272–274°C; IR (ATR) /cm−1: 3136, 3059, 3014 (arom. CH), 2921, 2874 (aliph. CH), 1725 (C=O); 1H NMR (DMSO-): /ppm 1.84 (s, 3H, Me), 6.93–6.95 (m, 1H, Ar-H), 7.57–7.97 (m, 4H, Ar-H), 8.26–8.46 (m, 2H, Ar-H); 13C NMR (DMSO-): /ppm 189.16 (C=O), 150.75 (Ar-C), 150.46 (Ar-C), 141.69 (Ar-C), 135.82 (Ar-C), 135.55 (Ar-CH), 132.79 (Ar-CH), 124.57 (Ar-CH), 124.51 (Ar-CH), 123.69 (Ar-CH), 122.86 (Ar-CH), 122.79 (Ar-CH), 121.52 (Ar-CH), 119.37 (Ar-CH), 115.00 (Ar-C), 112.98 (Ar-C), 14.04 (Me); MS: (ESI) 303.2 [M++1], 275.0 [M+−27], 220.0 [M+−82]. Anal. Calcd for C18H10N2O3: C, 71.52; H, 3.33; N, 9.27. Found: C, 71.58; H, 3.36; N, 9.23.

3-Methyl-4-(pyridin-2-yl)-5H-indeno[1,2-b]isoxazolo[4,5-e]pyridin-5-one (5h). Red powder (EtOH), Yield (73%), m.p. 276–278°C; IR (ATR) /cm−1: 3106, 3033 (arom. CH), 2920 (aliph. CH), 1716 (C=O); 1H NMR (DMSO-): /ppm 2.02 (s, 3H, Me), 7.60–7.72 (m, 3H, Ar-H), 7.78–7.86 (m, 2H, Ar-H), 7.99–8.80 (m, 3H, Ar-H); 13C NMR (DMSO-): 188.27 (C=O), 167.22 (Ar-C), 157.20 (Ar-C), 149.57 (Ar-C), 149.16 (Ar-C), 144.68 (Ar-C), 140.81 (Ar-C), 136.26 (Ar-C), 136.23 (Ar-CH), 135.91 (Ar-CH), 132.89 (Ar-CH), 125.67 (Ar-CH), 124.68 (Ar-CH), 123.83 (Ar-CH), 121.89 (Ar-CH), 121.81 (Ar-CH), 111.49 (Ar-C), 12.42 (Me); MS: (ESI) 314.3 [M++1], 286.0 [M+−27], 229.0 [M+−84], 216.0 [M+−97]. Anal. Calcd for C19H11N3O2: C, 72.84; H, 3.54; N, 13.41. Found: C, 72.91; H, 3.60; N, 13.35.

3-Methyl-7,8-dihydro-5H-spiro[indoline-3,4-isoxazolo[5,4-b]quinoline]-2,5(6H,9H)-dione (8a) Lit. [22]. White powder (EtOH), Yield (80%), m.p. 221–223°C; IR (ATR) /cm−1: 3337, 3222 (NH), 3127, 3028 (arom. CH), 2955, 2934, 2887 (aliph. CH), 1732 (C=O), 1686 (C=O); 1H NMR (DMSO-): /ppm 1.53 (s, 3H, Me), 1.90 (dd, 2H,  Hz,  Hz, CH2), 2.17 (ddd, 2H,  Hz,  Hz,  Hz, CH2), 2.64 (t, 2H,  Hz, CH2), 6.80 (d, 1H,  Hz, Ar-H), 6.87 (dtd, 2H,  Hz,  Hz,  Hz, Ar-H), 7.13 (td, 1H,  Hz,  Hz, Ar-H), 10.39 (s, 1H, NH), 11.08 (s, 1H, NH); 13C NMR (DMSO-): 193.70 (C=O), 178.86 (C=O), 159.51 (Ar-C), 157.08 (Ar-C), 154.15 (Ar-C), 141.40 (Ar-C), 135.99 (Ar-C), 127.73 (Ar-CH), 123.28 (Ar-CH), 121.65 (Ar-CH), 109.83 (Ar-C), 108.67 (Ar-CH), 93.80 (Ar-C), 48.73 (C), 36.79 (CH2), 27.39 (CH2), 20.89 (CH2), 8.78 (Me); MS: (ESI) 322.5 [M++1], 279.0 [M+−43], 251.0 [M+−71]. Anal. Calcd for C18H15N3O3: C, 67.28; H, 4.71; N, 13.08. Found: C, 67.36; H, 4.65; N, 13.12.

3-Methylspiro[indeno[2,1-e]isoxazolo[5,4-b]pyridine-4,3-indoline]-2,5(10H)-dione (8b). Orange powder (EtOH), Yield (88%), m.p. 242–244°C; IR (ATR) /cm−1: 3434, 3349 (NH), 3149, 3115, 3085 (arom. CH), 2912 (aliph. CH), 1741 (C=O), 1710 (C=O); 1H NMR (DMSO-): /ppm 1H NMR (DMSO-): /ppm 1.57 (s, 3H, Me), 6.70–7.10 (m, 4H, Ar-H), 7.25–7.93 (m, 4H, Ar-H), 10.63 (s, 1H, NH), 12.53 (s, 1H, NH); 13C NMR (DMSO-): /ppm 189.18 (C=O), 175.68 (C=O), 161.52 (Ar-C), 157.71 (Ar-C), 156.41 (Ar-C), 142.71 (Ar-C), 142.06 (Ar-C), 136.14 (Ar-CH), 132.31 (Ar-C), 130.83 (Ar-CH), 128.78 (Ar-CH), 128.13 (Ar-C), 122.67 (Ar-CH), 121.49 (Ar-CH), 120.85 (Ar-CH), 119.69 (Ar-CH), 109.85 (Ar-CH), 106.19 (Ar-C), 95.65 (Ar-C), 52.42 (C), 8.90 (Me); MS: (ESI) 354.1 [M+−1], 311.08 [M+−43], 284.4 [M+−71]. Anal. Calcd for C21H13N3O3: C, 70.98; H, 3.69; N, 11.83. Found: C, 71.05; H, 3.75; N, 11.87.

3-Methyl-5H-spiro[benzo[g]isoxazolo[5,4-b]quinoline-4,3-indoline]-2,5,10(11H)-trione (8c). Dark purple powder (EtOH), Yield (90%), m.p. 250–252°C; IR (ATR) /cm−1: 3376, 3280 (NH), 3178, 3072, 3014 (arom. CH), 2922 (aliph. CH), 1736 (C=O), 1699 (C=O), 1672 (C=O); 1H NMR (DMSO-): /ppm 1.62 (s, 3H, Me), 6.89–7.24 (m, 4H, Ar-H), 7.49–7.84 (m, 4H, Ar-H), 10.74 (s, 1H, NH), 11.83 (s, 1H, NH); 13C NMR (DMSO-): /ppm 180.99 (C=O), 179.12 (C=O), 178.32 (C=O), 169.42 (Ar-C), 159.74 (Ar-C), 157.09 (Ar-C), 155.32 (Ar-C), 141.10 (Ar-C), 135.97 (Ar-C), 135.08 (Ar-CH), 133.44 (Ar-CH), 130.02 (Ar-C), 128.55 (Ar-CH), 126.11 (Ar-CH), 125.83 (Ar-CH), 124.22 (Ar-CH), 122.08 (Ar-CH), 116.06 (Ar-C), 109.17 (Ar-CH), 93.90 (Ar-C), 49.80 (C), 8.86 (Me); MS: (ESI) 384.1 [M++1], 341.0 [M+−43], 325.0 [M+−58], 312.0 [M+−71], 297.2 [M+−86]. Anal. Calcd for C22H13N3O4: C, 68.93; H, 3.42; N, 10.96. Found: C, 69.05; H, 3.53; N, 11.85.

3-Methyl-6,7-dihydrospiro[cyclopenta[e]isoxazolo[5,4-b]pyridine-4,3-indoline]-2,5(8H)-dione (8d). White powder (EtOH), Yield (76%), m.p. 216–218°C; IR (ATR) /cm−1: 3340, 3220 (NH), 3125, 3025 (arom. CH), 2967, 2936, 2883 (aliph. CH), 1735 (C=O), 1689 (C=O); 1H NMR (DMSO-): /ppm 1.52 (s, 3H, Me), 2.33 (d, 2H,  Hz, CH2), 2.77 (br s, 2H, CH2), 6.83–7.00 (m, 3H, Ar-H), 7.20 (t, 1H,  Hz, Ar-H), 10.58 (s, 1H, NH), 11.69 (s, 1H, NH); 13C NMR (DMSO-): /ppm 199.32 (C=O), 177.45 (C=O), 166.86 (Ar-C), 161.74 (Ar-C), 157.46 (Ar-C), 141.44 (Ar-C), 133.79 (Ar-C), 128.44 (Ar-CH), 124.24 (Ar-CH), 122.03 (Ar-CH), 114.12 (Ar-C), 109.16 (Ar-CH), 94.37 (Ar-C), 46.85 (C), 33.55 (CH2), 24.12 (CH2), 8.84 (Me); MS: (ESI) 308.3 [M++1], 265.0 [M+−43], 238.0 [M+−70]. Anal. Calcd for C17H13N3O3: C, 66.44; H, 4.26; N, 13.67. Found: C, 66.52; H, 4.32; N, 13.70.

3. Results and Discussion

Initially, the three-component reaction of benzaldehyde (1.00 mmol), indan-1,3-dione (1.00 mmol), and 5-amino-3-methylisoxazole (1.00 mmol) was examined under ultrasonic irradiation without a catalyst at 40°C in 5 mL EtOH. The formation of compound 4a was completed in 300 minutes with a yield of 35%. When the same reaction was examined in the presence of 5 mol% (±)-CSA at 40°C under ultrasound irradiation, the product was obtained with a yield of 52% in 180 minutes (Table 1). Increasing the temperature to 70°C increased the yield to 58% and the reaction was completed in 120 minutes. In order to observe the effect of the amount of (±)-CSA on the reaction, experiments using different amounts of catalyst were performed (Table 1). The best result was obtained by carrying out the reaction using 15 mol% of (±)-CSA at 70°C under ultrasonic irradiation.

(±)-CSA (mol%)Temperature (°C)ConditionsTime (min)Yield



ProductArTime (min)Yield



Entry-DiketoneProductTime (min)Yield

a3080 [22]


Using the best optimized conditions, several isoxazolopyridine derivatives were synthesized at 70°C in the presence of 15 mol% (±)-CSA catalyst in EtOH under ultrasonic irradiation (Scheme 1). The results are summarized in Table 2.

It is important to point out the fact that for some unknown reasons the reaction involving 5-amino-3-methylisoxazole, indan-1,3-dione, and aromatic aldehydes gave isoxazolopyridines 5 or their dihydro derivatives 4 independently of the substituent carried by the aldehydes.

Then the spirooxindole derivatives were synthesized via multicomponent reaction of 5-amino-3-methylisoxazole, isatin, and -diketones in the presence of (±)-CSA catalyst under ultrasonic irradiation (Scheme 2). The best yields were observed in the presence of 10 mol% (±)-CSA in EtOH under ultrasonic irradiation at 70°C (Table 3).

The structure of the novel generated compounds was confirmed by Fourier transform-infrared (FTIR), 1H, 13C, APT NMR techniques, and mass spectroscopy. In the 1H NMR spectra of the isoxazolopyridines 4a–e, benzilic C-H proton resonated near 5.06–5.30 and in the 13C NMR spectra, the benzilic C-H carbon resonated near 27–37. The mass spectra of all novel compounds exhibited the expected molecular ion peak.

Generally, efficient HAT agents are the compounds which show high hydrogen atom donating ability, and they usually have low heteroatom-H bond dissociation energies. Abstraction of hydrogen from these compounds leads to C-centered radicals which are stabilized by resonance or the generation of sterically hindered radicals [47]. In this study, the antioxidant activity of the synthesized compounds 4a–e, 5f-g, and 8a–d was examined for free radical scavenging activity, reducing activity, metal chelating activity, superoxide scavenging activity, and total antioxidant activity.

The DPPH scavenging effect of isoxazolopyridine and spirooxindole compounds (4a–e, 5f–h, and 8a–d) and standards (BHA, BHT, Trolox, and Resorcinol) was studied and compounds 4a and 8a were found to be the ones with the most potential activity (Figure 1). These results indicate that the new synthesized compound had a moderate effect on the scavenging free radical. A higher DPPH radical scavenging activity is associated with a lower EC50 value.

As indicated in Figure 2, the reducing power of compounds 5f, 4c, 8a, and 4b at 400 μg/mL concentration is higher than the other synthesized compounds and the reducing power was increased by increasing the concentration.

The metal chelating activity for the ferrous ion of the new synthesized compounds was assayed by the inhibition of the red-colored ferrozine/FeCl2 complex. EDTA, Trolox, and BHT were used as standard compounds. The isoxazolopyridine and spirooxindole compounds showed moderate to good metal chelating activities at 25, 50, 100, 200, and 400 μg/mL concentrations (Figure 3). Compound 4b exhibited the highest chelating activity among the tested compounds at 400 μg/mL.

The superoxide scavenging activity of isoxazolopyridine and spirooxindole compounds was compared with the same concentrations of BHT, Trolox, and BHA. None of the compounds showed greater antioxidant activity than the standards. However, compounds 5g, 5h, 4e, and 4b exhibited higher inhibition than the other synthesized compounds (Figure 4).

Total antioxidant activity of the isoxazolopyridine and spirooxindole compounds was assayed by thiocyanate methodology. Compounds 4b and 8a showed effectual antioxidant activity (Figure 5). The results indicated that compound 4b had stronger total antioxidant activity than BHT, Resorcinol, and Ascorbic acid at the same concentration (100 μg/mL).

4. Conclusions

In conclusion, new isoxazolopyridine and spirooxindole compounds were synthesized via one-pot three-component reaction of 5-amino-3-methylisoxazole, indan-1,3-dione, and aromatic aldehydes and reaction of 5-amino-3-methylisoxazole, isatin, and -diketones in the presence of (±)-camphor-10-sulfonic acid under ultrasound-promoted conditions. This procedure provided a practical, simple, and efficient way to obtain isoxazolopyridines and spirooxindoles in moderate to high yields. The antioxidant activities of these compounds were determined. Compounds 4b, 4e, 5f, 5g, 5h, and 8a exhibited higher activities.

Conflicts of Interest

The author declares that there are no conflicts of interest regarding the publication of this paper.


This study was financially supported by Kirklareli University under Project no. KLUBAP 015. The author thanks Assistant Professor Dr. Melek Gul, Associate Professor Dr. Emine Bagdatli, and Assistant Professor Dr. Aliye Gediz Erturk for their guidance and helpful comments on antioxidant activity assays.

Supplementary Materials

The supplementary material includes the 1H and APT NMR spectrums of compounds 4b, 4c, 4e, 5f, 5h, 8a, 8d, and MS spectrums of compounds 4a, 4b, 5f, 5h, 8b, 8c.

  1. Supplementary Material


  1. A. Dömling, “Recent developments in isocyanide based multicomponent reactions in applied chemistry,” Chemical Reviews, vol. 106, no. 1, pp. 17–89, 2006. View at: Publisher Site | Google Scholar
  2. J. D. Sunderhaus and S. F. Martin, “Applications of multicomponent reactions to the synthesis of diverse heterocyclic scaffolds,” Chemistry—A European Journal, vol. 15, no. 6, pp. 1300–1308, 2009. View at: Publisher Site | Google Scholar
  3. J. Zhu, Q. Wang, and M. Wang, Multicomponent Reactions in Organic Synthesis, Wiley-VCH, Weinheim, Germany, 2014.
  4. T. J. J. Muller, Science of, Synthesis: Multicomponent Reactions, vol. 1, Thieme, 2014.
  5. K. Ameta and A. Dandia, Multicomponent Reactions: Synthesis of Bioactive Heterocycles, CRC Press, 2017.
  6. B. M. Trost, “The atom economy—a search for synthetic efficiency,” Science, vol. 254, no. 5037, pp. 1471–1477, 1991. View at: Publisher Site | Google Scholar
  7. R. P. Herrera and E. Marqués-López, Multicomponent Reactions. Concepts and Applications for Design and Synthesis, Wiley, 2015.
  8. S. S. Panda, P. V. R. Chowdary, and B. S. Jayashree, “Synthesis, antiinflammatory and antibacterial activity of novel indolyl-isoxazoles,” Indian Journal of Pharmaceutical Sciences, vol. 71, no. 6, pp. 684–687, 2009. View at: Publisher Site | Google Scholar
  9. J. Liu, Y. Sun, X. Zhang et al., “Spirooxindoles, a potential novel class of anti-inflammatory agents,” Inflammation and Cell Signaling, vol. 1, p. e372, 2014. View at: Google Scholar
  10. S. J. Wittenberger, “An efficient synthesis of the cholinergic channel activator ABT-418,” Journal of Organic Chemistry, vol. 61, no. 1, pp. 356–358, 1996. View at: Publisher Site | Google Scholar
  11. T. Tatee, K. Narita, S. Kurashige et al., “Isoxazole derivatives as centrally acting muscle relaxants. III. Synthesis and activity of conformationally restricted analogs,” Chemical and Pharmaceutical Bulletin, vol. 35, no. 9, pp. 3676–3690, 1987. View at: Publisher Site | Google Scholar
  12. M. M. M. Santos, “Recent advances in the synthesis of biologically active spirooxindoles,” Tetrahedron, vol. 70, no. 52, pp. 9735–9757, 2014. View at: Publisher Site | Google Scholar
  13. A. Kamal, P. Suresh, A. Mallareddy et al., “Synthesis of a new 4-aza-2,3-didehydropodophyllotoxin analogues as potent cytotoxic and antimitotic agents,” Bioorganic and Medicinal Chemistry, vol. 19, no. 7, pp. 2349–2358, 2011. View at: Publisher Site | Google Scholar
  14. F. Shi, X. N. Zeng, X. D. Cao et al., “Design and diversity-oriented synthesis of novel 1,4-thiazepen-3-ones fused with bioactive heterocyclic skeletons and evaluation of their antioxidant and cyctotoxic activities,” Bioorganic & Medicinal Chemistry Letters, vol. 22, pp. 743–746, 2012. View at: Google Scholar
  15. S. Mathusalini, T. Arasakumar, K. Lakshmi et al., “Synthesis and biological evaluation of new spirooxindoles with embedded pharmacophores,” New Journal of Chemistry, vol. 40, no. 6, pp. 5164–5169, 2016. View at: Publisher Site | Google Scholar
  16. B. Yu, D.-Q. Yu, and H.-M. Liu, “Spirooxindoles: Promising scaffolds for anticancer agents,” European Journal of Medicinal Chemistry, vol. 97, no. 1, pp. 673–698, 2015. View at: Publisher Site | Google Scholar
  17. M. Ur Rahman, A. Rathore, A. A. Siddiqui, G. Parveen, and M. Shahar Yar, “Synthesis and antihypertensive screening of new derivatives of quinazolines linked with isoxazole,” BioMed Research International, vol. 2014, Article ID 739056, 13 pages, 2014. View at: Publisher Site | Google Scholar
  18. M. Rowley, H. B. Broughton, I. Collins et al., “5-(4-Chlorophenyl)-4-methyl-3-(1-(2-phenylethyl)piperidin-4-yl)isoxazole: A potent, selective antagonist at human cloned dopamine D4 receptors,” Journal of Medicinal Chemistry, vol. 39, no. 10, pp. 1943–1945, 1996. View at: Publisher Site | Google Scholar
  19. A. R. Lingham, J. A. Hawley, T. Greaves, N. Jackson, F. Antolasic, and H. M. Hügel, “Revisiting the three component synthesis of isoxazolo[5,4-b]pyridines, 4-aryl-3,7,7-trimethyl-isoxazolo[5,4-b]quinolin-5(6H)-ones and related heterocycles,” Polyhedron, vol. 120, pp. 175–179, 2016. View at: Publisher Site | Google Scholar
  20. E. A. Muravyova, V. V. Tkachenko, S. M. Desenko et al., “Behavior of 5-amino-3-methylisoxazole in multicomponent heterocyclizations with carbonyl compounds under thermal heating and non-classical conditions,” Arkivoc, vol. 2013, no. 3, pp. 338–371, 2013. View at: Publisher Site | Google Scholar
  21. S.-J. Tu, X.-H. Zhang, Z.-G. Han et al., “Synthesis of isoxazolo[5,4-b]pyridines by microwave-assisted multi-component reactions in water,” Journal of Combinatorial Chemistry, vol. 11, no. 3, pp. 428–432, 2009. View at: Publisher Site | Google Scholar
  22. P. Yuvaraj, K. Manivannan, and B. S. R. Reddy, “Microwave-assisted efficient and highly chemoselective synthesis of oxazolo[5,4-B]quinoline-fused spirooxindoles via catalyst- and solvent-free three-component tandem Knoevenagel/Michael addition reaction,” Tetrahedron Letters, vol. 56, no. 1, pp. 78–81, 2015. View at: Publisher Site | Google Scholar
  23. T. L. Pavlovska, R. G. Redkin, V. V. Lipson, and D. V. Atamanuk, “Molecular diversity of spirooxindoles. Synthesis and biological activity,” Molecular Diversity, vol. 20, no. 1, pp. 299–344, 2016. View at: Publisher Site | Google Scholar
  24. D. Cheng, Y. Ishihara, B. Tan, and C. F. Barbas, “Organocatalytic asymmetric assembly reactions: Synthesis of spirooxindoles via organocascade strategies,” ACS Catalysis, vol. 4, no. 3, pp. 743–762, 2014. View at: Publisher Site | Google Scholar
  25. H. J. Roh, S. Y. Kim, B. K. Min, and J. N. Kim, “An efficient synthesis of dihydrofuranyl spirooxindoles from isatin-derived propargylic alcohols and 1,3-dicarbonyls,” Tetrahedron Letters, vol. 58, no. 1, pp. 21–24, 2017. View at: Publisher Site | Google Scholar
  26. A. V. Moradi, “A multicomponent reaction as a versatile tool for the synthesis of spirooxindoles using N-alkylisatins; efficient catalysis by ZnO nanoparticles,” Journal of Chemical Research, vol. 41, no. 1, pp. 7–11, 2017. View at: Publisher Site | Google Scholar
  27. L. Yan and Y. Wang, “Recent advances in green synthesis of 3,3-spirooxindoles via isatin-based one-pot multicomponent cascade reactions in aqueous medium,” ChemistrySelect, vol. 1, no. 21, pp. 6948–6960, 2016. View at: Publisher Site | Google Scholar
  28. M. Esmaeilpour, J. Javidi, and M. Divar, “A green one-pot three-component synthesis of spirooxindoles under conventional heating conditions or microwave irradiation by using Fe3O4@SiO2-imid-PMAn magnetic porous nanospheres as a recyclable catalyst,” Journal of Magnetism and Magnetic Materials, vol. 423, pp. 232–240, 2017. View at: Publisher Site | Google Scholar
  29. A. Srivastava, S. Singh, and S. Samanta, “(±)-CSA catalyzed Friedel-Crafts alkylation of indoles with 3-ethoxycarbonyl-3-hydoxyisoindolin-1-one: an easy access of 3-ethoxycarbonyl-3-indolylisoindolin-1-ones bearing a quaternary α-amino acid moiety,” Tetrahedron Letters, vol. 54, no. 11, pp. 1444–1448, 2013. View at: Publisher Site | Google Scholar
  30. X. Jiang, Z. Song, C. Xu, Q. Yao, and A. Zhang, “(D,L)-10-camphorsulfonic-acid-catalysed synthesis of diaryl-fused 2,8-dioxabicyclo[3.3.1]nonanes from 2-hydroxychalcones and naphthol derivatives,” European Journal of Organic Chemistry, vol. 2014, no. 2, pp. 418–425, 2014. View at: Publisher Site | Google Scholar
  31. E. Pelit and Z. Turgut, “(+)-CSA catalyzed multicomponent synthesis of 1-[(1,3-thiazol-2-ylamino)methyl]-2-naphthols and their ring-closure reaction under ultrasonic irradiation,” Journal of Chemistry, vol. 2016, Article ID 9315614, 9 pages, 2016. View at: Publisher Site | Google Scholar
  32. A. Srivastava, S. M. Mobin, and S. Samanta, “(±)-CSA catalyzed one-pot synthesis of 6,7-dihydrospiro[indole-3,1-isoindoline]-2,3,4(1H,5H)-trione derivatives: easy access of spirooxindoles and ibophyllidine-like alkaloids,” Tetrahedron Letters, vol. 55, no. 11, pp. 1863–1867, 2014. View at: Publisher Site | Google Scholar
  33. R. M. Kellogg, J. W. Nieuwenhuijzen, K. Pouwer et al., “Dutch resolution: separation of enantiomers with families of resolving agents. A status report,” Synthesis, no. 10, pp. 1626–1638, 2003. View at: Google Scholar
  34. T. J. Mason, “Sonochemistry and the environment—providing a ‘green’ link between chemistry, physics and engineering,” Ultrasonics Sonochemistry, vol. 14, no. 4, pp. 476–483, 2007. View at: Publisher Site | Google Scholar
  35. M. Vinatoru, E. Bartha, F. Badea, and J. L. Luche, “Sonochemical and thermal redox reactions of triphenylmethane and triphenylmethyl carbinol in nitrobenzene,” Ultrasonics Sonochemistry, vol. 5, no. 1, pp. 27–31, 1998. View at: Publisher Site | Google Scholar
  36. E. Pelit and Z. Turgut, “Three-component aza-Diels-Alder reactions using Yb(OTf)3 catalyst under conventional/ultrasonic techniques,” Ultrasonics Sonochemistry, vol. 21, no. 4, pp. 1600–1607, 2014. View at: Publisher Site | Google Scholar
  37. J. L. Luche, Synthetic Organic Sonochemistry, Plenium Press, New York, NY, USA, 1998.
  38. C. Dong, K. Sanjay, and M. Ackmez, Handbook on Applications of Ultrasound Sonochemistry for Sustainability, CRC Press; Taylor & Francis Group, Boca Raton, Fla, USA, 2011.
  39. E. Pelit, “CSA catalyzed multi-component synthesis of polycyclic pyrazolo[4,3-e]pyridines under ultrasonic irradiation and their antioxidant activity,” Journal of the Turkish Chemical Society, Section A: Chemistry, vol. 4, pp. 631–648, 2017. View at: Google Scholar
  40. E. Pelit, “(±)-CSA catalyzed multicomponent synthesis of indeno naphthopyrans and tetrahydrobenzo[a]xanthen-11-ones under ultrasonic irradiation,” Chemical Science International Journal, vol. 20, no. 1, Article ID CSIJ.35380, 8 pages, 2017. View at: Publisher Site | Google Scholar
  41. H. Sies, “Oxidative stress: oxidants and antioxidants,” Experimental Physiology, vol. 82, no. 2, pp. 291–295, 1997. View at: Publisher Site | Google Scholar
  42. W. Brand-Williams, M. E. Cuvelier, and C. Berset, “Use of a free radical method to evaluate antioxidant activity,” LWT—Food Science and Technology, vol. 28, no. 1, pp. 25–30, 1995. View at: Publisher Site | Google Scholar
  43. M. Oyaizu, “Studies on product of browning reaction prepared from glucose amine,” Japanese Journal of Nutrition, vol. 44, pp. 307–315, 1986. View at: Publisher Site | Google Scholar
  44. E. A. Decker and B. Welch, “Role of ferritin as a lipid oxidation catalyst in muscle food,” Journal of Agricultural and Food Chemistry, vol. 38, no. 3, pp. 674–677, 1990. View at: Publisher Site | Google Scholar
  45. F. Liu, V. E. C. Ooi, and S. T. Chang, “Free radical scavenging activities of mushroom polysaccharide extracts,” Life Sciences, vol. 60, no. 10, pp. 763–771, 1997. View at: Publisher Site | Google Scholar
  46. H. Mitsuda, K. Yuasumoto, and K. Iwama, “Antioxidative action of indole compounds during the autooxidation of linoleic acid,” Japanese Society of Nutrition and Food Science, vol. 19, pp. 210–214, 1996. View at: Google Scholar
  47. D. Huang, B. Ou, and R. L. Prior, “The chemistry behind antioxidant capacity assays,” Journal of Agricultural and Food Chemistry, vol. 53, no. 6, pp. 1841–1856, 2005. View at: Publisher Site | Google Scholar

Copyright © 2017 Emel Pelit. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.